Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Constellation Software file a Schedule 13D on Sabre or publicly announce a strategic transaction push before December 31, 2026?
Current Prediction
Why This Question Matters
Tests whether the 15% standstill (through Q1 2027) holds or breaks. A 13D filing or strategic-push announcement would be a meaningful break in the activism settlement — flagged as TAIL_RISK_SEVERITY escalation by black-swan-beacon. NO is the consensus expectation given the standstill. YES would mean either Constellation breached or a friendly transaction is being formed; either way materially shifts GOVERNANCE_ALIGNMENT and forces re-rating.
Prediction Distribution
Individual Predictions(9 runs)
Standstill is contractually binding through Q1 2027 — explicit bar. Year-1 standstill respect rate ~95%. Constellation patient-capital model + Technology Committee placement signals long-term operator. Strategic transaction announcements during active standstill ~3-5%. Net: ~8-12%. Pick 10%.
Constellation has zero precedent for breaking settled-activism standstill. Their model (compound through patient ownership) is incompatible with mid-standstill activism. Friendly take-private signaled in 2026 would be premature given standstill expiration in Q1 2027. Lean low. ~8%.
Tail cases for YES: (1) catastrophic Q1 miss + activism settlement clause material adverse change triggers; (2) friendly take-private package announced before Q1 2027 with mutual agreement to dissolve standstill; (3) third-party activist enters above 5% threshold, forcing Constellation defensive disclosure. Sum ~10-15%. Pick 12%.
Year-1 standstill respect ~95% + Constellation specific patient-capital model. Strategic transaction announcement during standstill is unusual but not impossible. ~10%.
Standstill explicitly bars 13D filing. Strategic transaction announcement requires Sabre Board approval — Board is not under takeover pressure. ~9%.
Constellation has potential motive (cost basis $1.16 = 60%+ IRR at $1.82) but standstill economics + reputational protection of long-term-holder brand keep them disciplined. Slight upward bias from strategic-transaction-with-mutual-consent. ~12%.
Standstill through Q1 2027. Year-1 respect rate 95%. ~10%.
Constellation patient capital model + standstill discipline. ~9%.
Tail scenarios: MAC trigger or mutual strategic transaction announcement. Both low probability. ~11%.
Resolution Criteria
Resolves YES if (a) Constellation Software (or any of its affiliates including Topicus, Lumine Group, Constellation Software Inc.) files a Schedule 13D with the SEC regarding Sabre Corporation common stock at any point on or before December 31, 2026, OR (b) Sabre or Constellation publicly announces a strategic transaction (sale, merger, take-private, joint venture, or material stake increase above 15%) before December 31, 2026. Resolves NO otherwise.
Resolution Source
SEC EDGAR filings, Sabre press releases, Constellation Software press releases
Source Trigger
Constellation accumulates above 13G threshold or files 13D
Full multi-lens equity analysis